This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

TPHA / FTA-ABS

Authoring team

Both the Treponema pallidum haemagglutination assay and the fluorescent Treponema antibody tests are highly specific for Treponema antigens:

  • TPHA - sheep red blood cells coated with T. pallidum are agglutinated by patient's antibody
  • FTA-ABS - T. pallidum is fixed to a microscope slide, antibodies in patient's serum attach and are detected by the addition of fluorescent anti-human immunoglobulin. The test is positive in 90% of patients with primary infection and positive in all patients with secondary or tertiary infection. It can be adapted to detect either IgG or IgM antibody. This test becomes positive in early disease (at about 3-4 weeks after infection - at the same time as the reagin tests).

False positives may result from non-sexually transmitted treponemal diseases of the tropics - such as Yaws and Pinta. Differentiation requires a careful history and examination.

In some texts the THPA is referred to as the microhaemagglutination assay for antibodies to Treponema pallidum.


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.